MCID: BRS044
MIFTS: 60

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 30 6 15 17 74
Mammary Adenocarcinoma 12 74
Adenocarcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 51 C5214

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and inflammatory breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Paclitaxel and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 32.9 EGFR ERBB2 ESR1
2 inflammatory breast carcinoma 32.5 EGFR ERBB2 ESR1
3 breast medullary carcinoma 32.3 ERBB2 ESR1
4 adenocarcinoma 31.9 AKT1 EGF EGFR ERBB2 H19 KRAS
5 cystadenocarcinoma 30.6 AKT1 ERBB2 PIK3CA TP53
6 squamous cell carcinoma 30.4 AKT1 EGF EGFR ERBB2 H19 PIK3CA
7 ovarian cancer 1 30.3 AKT1 ERBB2 KRAS PIK3CA TP53
8 gastrointestinal stromal tumor 30.3 AKT1 EGFR KRAS TP53
9 lung squamous cell carcinoma 30.2 AKT1 EGFR KRAS PIK3CA TP53
10 bone resorption disease 30.2 CTSK ESR1 TNFSF11
11 glioblastoma multiforme 30.2 AKT1 CDKN1A EGF EGFR ERBB2 PIK3CA
12 glioblastoma 30.1 AKT1 CDKN1A EGF EGFR ERBB2 H19
13 glioma 30.0 BAX CDKN1A EGF EGFR ERBB2 H19
14 rheumatoid arthritis 29.9 CTSK FOS H19 MMP9 TNFSF11
15 gastric adenocarcinoma 29.9 AKT1 BAX CASP8 EGF EGFR ERBB2
16 hepatocellular carcinoma 29.6 AKT1 BAX CASP8 CASP9 CDKN1A EGFR
17 ovarian cancer 29.5 AKT1 BAX CASP8 CDKN1A EGF EGFR
18 colorectal cancer 29.2 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
19 prostate cancer 29.1 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
20 breast cancer 28.8 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
21 breast signet ring cell adenocarcinoma 11.1
22 breast mucinous carcinoma 11.1
23 breast secretory carcinoma 11.1
24 glycogen-rich clear cell breast carcinoma 11.1
25 acinic cell breast carcinoma 11.1
26 breast apocrine carcinoma 11.1
27 oncocytic breast carcinoma 11.1
28 uterine corpus serous adenocarcinoma 10.6 ERBB2 PIK3CA TP53
29 uterine body mixed cancer 10.6 ERBB2 PIK3CA TP53
30 anal squamous cell carcinoma 10.6 AKT1 PIK3CA TP53
31 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 KRAS PIK3CA TP53
32 glassy cell carcinoma of the cervix 10.6 ERBB2 ESR1
33 serous cystadenocarcinoma 10.6 AKT1 ERBB2 PIK3CA TP53
34 breast benign neoplasm 10.6 ERBB2 ESR1 TP53
35 thoracic benign neoplasm 10.6 ERBB2 ESR1 TP53
36 breast intraductal proliferative lesion 10.6 EGFR ERBB2
37 barrett's adenocarcinoma 10.6 ERBB2 KRAS TP53
38 ovarian clear cell carcinoma 10.6 KRAS PIK3CA TP53
39 bile duct adenocarcinoma 10.6 AKT1 KRAS TP53
40 fallopian tube carcinoma 10.6 ERBB2 ESR1 TP53
41 carcinosarcoma 10.6 ERBB2 KRAS PIK3CA TP53
42 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
43 uterine corpus cancer 10.6 ERBB2 ESR1 PIK3CA TP53
44 brain ependymoma 10.6 EGFR TP53
45 microglandular adenosis 10.6 EGFR ERBB2 TP53
46 female breast cancer 10.6 ERBB2 ESR1 TP53
47 adult hepatocellular carcinoma 10.6 CASP8 EGF PIK3CA TP53
48 pulmonary blastoma 10.6 EGFR KRAS TP53
49 suppressor of tumorigenicity 3 10.6 BAX CDKN1A TP53
50 primary peritoneal carcinoma 10.6 EGFR ERBB2 TP53

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.32 EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.32 KRAS
3 Decreased viability GR00221-A-1 10.32 AKT1 EGFR ESR1 KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.32 AKT1 ESR1 KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.32 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.32 AKT1 EGFR ESR1 PIK3CA ERBB2
7 Decreased viability GR00301-A 10.32 KRAS
8 Decreased viability GR00381-A-1 10.32 KRAS
9 Decreased viability GR00402-S-2 10.32 AKT1 EGFR ESR1 KRAS PIK3CA ERBB2
10 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AKT1 BAX CASP8 CASP9 CDKN1A SLC22A18
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AKT1 BAX CASP8 CASP9 CDKN1A SLC22A18
12 Decreased HIV-LTR-beta-galactosidase protein expression GR00224-A-1 9.46 AKT1 CYCS MMP9 RB1CC1

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
2 growth/size/body region MP:0005378 10.51 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
3 endocrine/exocrine gland MP:0005379 10.49 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
4 immune system MP:0005387 10.48 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
5 cardiovascular system MP:0005385 10.44 AKT1 CASP8 CASP9 CDKN1A CYCS EGFR
6 hematopoietic system MP:0005397 10.44 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
7 homeostasis/metabolism MP:0005376 10.43 AKT1 BAX CASP8 CDKN1A CTSK EGFR
8 behavior/neurological MP:0005386 10.41 AKT1 BAX CDKN1A CYCS ERBB2 ESR1
9 mortality/aging MP:0010768 10.4 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
10 embryo MP:0005380 10.38 AKT1 CASP8 CASP9 CDKN1A CYCS EGFR
11 integument MP:0010771 10.38 AKT1 CASP8 CDKN1A EGF EGFR ERBB2
12 craniofacial MP:0005382 10.31 CASP9 CDKN1A CTSK CYCS EGFR ERBB2
13 nervous system MP:0003631 10.31 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
14 digestive/alimentary MP:0005381 10.3 CDKN1A CTSK EGF EGFR ERBB2 ESR1
15 muscle MP:0005369 10.29 AKT1 BAX CASP8 CDKN1A EGFR ERBB2
16 neoplasm MP:0002006 10.27 AKT1 BAX CASP8 CDKN1A EGFR ERBB2
17 limbs/digits/tail MP:0005371 10.26 BAX CDKN1A CTSK EGFR ERBB2 ESR1
18 adipose tissue MP:0005375 10.11 AKT1 CDKN1A EGFR ESR1 PIK3CA TP53
19 liver/biliary system MP:0005370 10.11 AKT1 CASP8 CDKN1A EGFR ESR1 KRAS
20 normal MP:0002873 10.07 AKT1 EGF EGFR ERBB2 ESR1 FOS
21 reproductive system MP:0005389 10.07 AKT1 BAX CDKN1A EGF EGFR ERBB2
22 hearing/vestibular/ear MP:0005377 10.05 BAX CDKN1A EGFR FOS KRAS TP53
23 no phenotypic analysis MP:0003012 10.01 CDKN1A EGFR ESR1 KRAS PIK3CA RB1CC1
24 respiratory system MP:0005388 9.97 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
25 renal/urinary system MP:0005367 9.92 BAX CASP8 CDKN1A EGFR ESR1 KRAS
26 skeleton MP:0005390 9.8 AKT1 BAX CDKN1A CTSK CYCS EGFR
27 vision/eye MP:0005391 9.32 BAX CDKN1A EGF EGFR FOS KRAS

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33069-62-4 36314
2
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
3
Sodium Citrate Approved, Investigational Phase 3 68-04-2
4
Tamoxifen Approved Phase 3 10540-29-1 2733526
5
Zoledronic Acid Approved Phase 3 118072-93-8 68740
6
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
8
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Atezolizumab Approved, Investigational Phase 3,Phase 2 1380723-44-3
10
Pertuzumab Approved Phase 3,Phase 2 380610-27-5, 145040-37-5 2540
11
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
12
Goserelin Approved Phase 3 65807-02-5 5311128 47725
13
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
14
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
15
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
16
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
17
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
19
Emodepside Investigational, Vet_approved Phase 3,Phase 1,Phase 2 155030-63-0
20
Entinostat Investigational Phase 3,Phase 1 209783-80-2
21 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
22 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
23 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Early Phase 1
26 Immunologic Factors Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27 Antibodies Phase 3,Phase 2,Phase 1
28 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2
33 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
34 Estrogen Receptor Antagonists Phase 3,Phase 2
35 Selective Estrogen Receptor Modulators Phase 3
36 Steroid Synthesis Inhibitors Phase 3,Phase 2
37 Anticoagulants Phase 3
38 Estrogens Phase 3,Phase 1,Phase 2,Not Applicable
39 Chelating Agents Phase 3
40 Estrogen Antagonists Phase 3,Phase 2
41 Bone Density Conservation Agents Phase 3
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
43 Aromatase Inhibitors Phase 3,Phase 2
44 Citrate Phase 3
45 Calcium, Dietary Phase 3
46 Estrogen Receptor Modulators Phase 3
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
48 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
49 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed NCT00869206 Phase 3 zoledronic acid
3 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Recruiting NCT03337724 Phase 2, Phase 3 Ipatasertib;Paclitaxel;Placebo
4 Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer Recruiting NCT03199885 Phase 3 Atezolizumab;Paclitaxel
5 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
6 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin Acetate
7 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
8 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
9 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Active, not recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
10 Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
11 Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients Unknown status NCT01292408 Phase 2 Hydrochloroquine
12 Study of MDX-010 in Stage IV Breast Cancer Completed NCT00083278 Phase 2 MDX-010
13 Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Completed NCT00039520 Phase 2 docetaxel;sulindac
14 Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer Completed NCT00019916 Phase 1, Phase 2
15 Chemotherapy in Treating Women With Metastatic Breast Cancer Completed NCT00004046 Phase 2 exatecan mesylate
16 A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer Completed NCT02301988 Phase 2 Ipatasertib;Paclitaxel;Placebo
17 Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes Completed NCT01693549 Phase 2 Cabazitaxel
18 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
19 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility Completed NCT00591851 Phase 2 AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
20 IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma Recruiting NCT02614833 Phase 2 Placebo;Paclitaxel
21 Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Recruiting NCT01928589 Phase 1, Phase 2
22 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 Atezolizumab;Nab-paclitaxel
23 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting NCT03106415 Phase 1, Phase 2 Binimetinib
24 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
25 Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Recruiting NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
26 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Recruiting NCT03250676 Phase 1, Phase 2 H3B-6545
27 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
28 CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
29 Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Active, not recruiting NCT02894398 Phase 2 Palbociclib;Letrozole;Anastrozole;Exemestane;Fulvestrant
30 A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Active, not recruiting NCT02322814 Phase 2 Cobimetinib;Paclitaxel;Placebo;Atezolizumab;Nab-Paclitaxel
31 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients Active, not recruiting NCT01097642 Phase 2 Cetuximab;Ixabepilone
32 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting NCT01730833 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
33 Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
34 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Active, not recruiting NCT01593020 Phase 2 Paclitaxel;Eribulin;5-Fluorouracil;Epirubicin;Cyclophosphamide;Doxorubicin
35 Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer Terminated NCT00074269 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methotrexate
36 Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Withdrawn NCT03666819 Phase 2
37 Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
38 Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast Completed NCT02204046 Phase 1 BIWA 4
39 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Completed NCT00003761 Phase 1
40 Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer Completed NCT01502592 Phase 1
41 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
42 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Recruiting NCT02824575 Phase 1 Rebastinib;Paclitaxel;Eribulin Mesylate
43 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Recruiting NCT01724606 Phase 1 Sorafenib
44 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Recruiting NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
45 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Recruiting NCT02453620 Phase 1 Entinostat
46 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
47 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma Recruiting NCT02783300 Phase 1 GSK3326595.
48 Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer Not yet recruiting NCT03749850 Phase 1 LTLD;Cyclophosphamide
49 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Terminated NCT00071942 Phase 1
50 Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 30

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

42
Breast, Lung, Bone, Prostate, Brain, T Cells, Colon

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 960)
# Title Authors Year
1
Cytotoxic and Anticancer Effects of ICD-85 (Venom Derived Peptides) in Human Breast Adenocarcinoma and Normal Human Dermal Fibroblasts. ( 31089358 )
2019
2
Dietary baker's yeast sensitizes Ehrlich mammary adenocarcinoma to paclitaxel in mice bearing tumor. ( 31002367 )
2019
3
Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines. ( 30913467 )
2019
4
Triiodothyronine (T3) upregulates the expression of proto-oncogene TGFA independent of MAPK/ERK pathway activation in the human breast adenocarcinoma cell line, MCF7. ( 30916164 )
2019
5
Effect of curcumin-nanoemulsion associated with photodynamic therapy in breast adenocarcinoma cell line. ( 30926313 )
2019
6
Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. ( 30766885 )
2019
7
Liposomal Taro Lectin Nanocapsules Control Human Glioblastoma and Mammary Adenocarcinoma Cell Proliferation. ( 30699910 )
2019
8
Toward steroidal anticancer drugs: Non-parametric and 3D-QSAR modeling of 17-picolyl and 17-picolinylidene androstanes with antiproliferative activity on breast adenocarcinoma cells. ( 30594032 )
2018
9
Induction of Apoptosis and Cytotoxicity by Raphasatin in Human Breast Adenocarcinoma MCF-7 Cells. ( 30486382 )
2018
10
Death Mechanism of Breast Adenocarcinoma Cells Caused by BRET-Induced Cytotoxicity of miniSOG Depends on the Intracellular Localization of the NanoLuc-miniSOG Fusion Protein. ( 30397895 )
2018
11
Zerumbone-Loaded Nanostructured Lipid Carrier Induces Apoptosis of Canine Mammary Adenocarcinoma Cells. ( 30410940 )
2018
12
Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells. ( 30352078 )
2018
13
68Ga-Prostate-Specific Membrane Antigen PET/CT and 18F-FDG PET/CT of Primary Signet Ring Cell Breast Adenocarcinoma. ( 30247208 )
2018
14
Paclitaxel delivery system based on poly(lactide-co-glycolide) microparticles and chitosan thermo-sensitive gel for mammary adenocarcinoma treatment. ( 30182425 )
2018
15
Cucumol B, a new triterpene benzoate from Cucumis melo seeds with cytotoxic effect toward ovarian and human breast adenocarcinoma. ( 29947257 )
2018
16
FMSP-Nanoparticles Induced Cell Death on Human Breast Adenocarcinoma Cell Line (MCF-7 Cells): Morphometric Analysis. ( 29882888 )
2018
17
Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo. ( 29842818 )
2018
18
Association of surgical approach with complication rate, progression-free survival time, and disease-specific survival time in cats with mammary adenocarcinoma: 107 cases (1991-2014). ( 29772965 )
2018
19
Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway. ( 29775573 )
2018
20
Gadopentatic acid affects in vitro proliferation and doxorubicin response in human breast adenocarcinoma cells. ( 29728885 )
2018
21
Metabolomics analysis of the potential anticancer mechanism of annonaceous acetogenins on a multidrug resistant mammary adenocarcinoma cell. ( 29750943 )
2018
22
Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. ( 29138806 )
2018
23
Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. ( 29179603 )
2018
24
Chitosan-Cellulose Multifunctional Hydrogel Beads: Design, Characterization and Evaluation of Cytocompatibility with Breast Adenocarcinoma and Osteoblast Cells. ( 29315214 )
2018
25
Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )
2018
26
Enhancing the Therapeutic Efficacy of Tamoxifen Citrate Loaded Span-Based Nano-Vesicles on Human Breast Adenocarcinoma Cells. ( 29470829 )
2018
27
Raman Spectroscopic Signatures Reveal Distinct Biochemical and Temporal Changes in Irradiated Human Breast Adenocarcinoma Xenografts. ( 29474157 )
2018
28
Improving of Anticancer Activity and Solubility of Cisplatin by Methylglycine and Methyl Amine Ligands Against Human Breast Adenocarcinoma Cell Line. ( 29516403 )
2018
29
Gold and Silver Nanoparticles Biomimetically Synthesized Using Date Palm Pollen Extract-Induce Apoptosis and Regulate p53 and Bcl-2 Expression in Human Breast Adenocarcinoma Cells. ( 29552710 )
2018
30
Assessment of synergistic effect of combining hyperthermia with irradiation and calcium carbonate nanoparticles on proliferation of human breast adenocarcinoma cell line (MCF-7 cells). ( 29616844 )
2018
31
Baicalein disturbs the morphological plasticity and motility of breast adenocarcinoma cells depending on the tumor microenvironment. ( 29667279 )
2018
32
CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. ( 29446767 )
2018
33
TPEN Exerts Antitumor Efficacy in Murine Mammary Adenocarcinoma Through an H2O2 Signaling Mechanism Dependent on Caspase-3. ( 29697031 )
2018
34
Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line. ( 28092843 )
2017
35
Efficient T3P® mediated synthesis, differential cytotoxicity and apoptosis induction by indolo-triazolo-thiadiazoles in human breast adenocarcinoma cells. ( 28235427 )
2017
36
Persian Gulf Jellyfish (Cassiopea andromeda) Venom Fractions Induce Selective Injury and Cytochrome C Release in Mitochondria Obtained from Breast Adenocarcinoma Patients ( 28240847 )
2017
37
Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells. ( 28270066 )
2017
38
Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. ( 28461972 )
2017
39
Vanadium(III)-l-cysteine enhances the sensitivity of murine breast adenocarcinoma cells to cyclophosphamide by promoting apoptosis and blocking angiogenesis. ( 28466788 )
2017
40
The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma. ( 28527736 )
2017
41
HER2/Topoisomerase IIa co-amplified breast adenocarcinoma "mirror" cases with different Topoisomerase IIa expression patterns. ( 28534385 )
2017
42
Remote Development of Tumor-to-Tumor Metastasis of Breast Adenocarcinoma in a Renal Oncocytoma. ( 28551171 )
2017
43
Phenolics from Rubus fairholmianus induces cytotoxicity and apoptosis in human breast adenocarcinoma cells. ( 28803117 )
2017
44
hsa-miR-1973 MicroRNA is Significantly and Differentially Expressed in MDA-MB-231 Cells of Breast Adenocarcinoma and Xenografts Derived from the Tumor. ( 28948560 )
2017
45
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. ( 29147603 )
2017
46
Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60]fullerene in a murine model of breast adenocarcinoma. ( 29180866 )
2017
47
Derivatives of alkyl gallate triphenylphosphonium exhibit antitumor activity in a syngeneic murine model of mammary adenocarcinoma. ( 28647477 )
2017
48
Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes. ( 28745079 )
2017
49
In vitro and in vivo antitumour effects of phenylboronic acid against mouse mammary adenocarcinoma 4T1 and squamous carcinoma SCCVII cells. ( 29072095 )
2017
50
The application of the linear quadratic model to compensate the effects of prolonged fraction delivery time on a Balb/C breast adenocarcinoma tumor: An in vivo study. ( 26630280 )
2016

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh38 Chromosome 8, 52623768: 52685459
2 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh37 Chromosome 8, 53536328: 53598019
3 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh38 Chromosome 8, 52624761: 52661660
4 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh37 Chromosome 8, 53537321: 53574220
5 SLC22A18 NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848 insertion Pathogenic
6 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
7 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
8 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
9 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
10 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
11 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
12 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
13 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
16 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
17 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
21 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
22 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 AKT1 CASP8 CASP9 CDKN1A CTSK EGF
2
Show member pathways
14.05 AKT1 BAX CASP8 CASP9 CYCS EGF
3
Show member pathways
14.03 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
4
Show member pathways
13.9 AKT1 CDKN1A EGF EGFR ERBB2 ESR1
5
Show member pathways
13.86 AKT1 BAX CASP8 CASP9 CDKN1A EGFR
6
Show member pathways
13.72 AKT1 BAX CDKN1A EGF EGFR ERBB2
7
Show member pathways
13.69 AKT1 BAX CASP8 CASP9 CYCS KRAS
8
Show member pathways
13.65 AKT1 CASP9 CDKN1A CTSK EGF EGFR
9
Show member pathways
13.61 AKT1 BAX CASP9 CDKN1A EGF EGFR
10
Show member pathways
13.56 AKT1 CDKN1A EGF EGFR ERBB2 FOS
11
Show member pathways
13.5 AKT1 BAX CASP8 CASP9 EGF EGFR
12
Show member pathways
13.46 AKT1 CASP8 EGF EGFR ERBB2 ESR1
13
Show member pathways
13.41 AKT1 BAX CYCS EGF EGFR ERBB2
14
Show member pathways
13.22 AKT1 EGFR ESR1 FOS KRAS MMP9
15
Show member pathways
13.19 AKT1 BAX CASP8 CASP9 CDKN1A EGF
16
Show member pathways
13.17 AKT1 EGF EGFR FOS KRAS MMP9
17
Show member pathways
13.14 AKT1 CASP8 CASP9 CYCS EGFR FOS
18
Show member pathways
13.12 AKT1 BAX CDKN1A CYCS FOS TP53
19
Show member pathways
13.1 AKT1 EGF EGFR ERBB2 FOS KRAS
20
Show member pathways
13.1 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
21
Show member pathways
13.09 AKT1 EGF EGFR ERBB2 FOS KRAS
22
Show member pathways
13.03 AKT1 CASP9 EGFR ERBB2 KRAS PIK3CA
23
Show member pathways
13 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
24 12.99 AKT1 CASP8 CASP9 EGF EGFR ERBB2
25
Show member pathways
12.95 AKT1 CASP9 CDKN1A EGF EGFR ERBB2
26
Show member pathways
12.94 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
27
Show member pathways
12.91 BAX CASP8 CASP9 CDKN1A CYCS ESR1
28
Show member pathways
12.91 AKT1 BAX CASP9 CYCS ERBB2 ESR1
29
Show member pathways
12.9 AKT1 CDKN1A FOS KRAS PIK3CA
30
Show member pathways
12.9 AKT1 CASP8 CASP9 CYCS EGFR FOS
31
Show member pathways
12.89 AKT1 BAX CASP8 CASP9 CYCS EGF
32
Show member pathways
12.88 AKT1 CDKN1A EGFR FOS KRAS
33
Show member pathways
12.87 AKT1 EGF EGFR KRAS PIK3CA
34 12.86 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
35
Show member pathways
12.83 AKT1 CASP8 CASP9 CYCS FOS PIK3CA
36
Show member pathways
12.81 AKT1 CDKN1A EGF EGFR ERBB2 FOS
37
Show member pathways
12.8 AKT1 BAX CASP9 CYCS EGF EGFR
38
Show member pathways
12.77 AKT1 BAX CDKN1A EGF EGFR ERBB2
39
Show member pathways
12.75 AKT1 CASP9 FOS KRAS PIK3CA
40 12.75 CDKN1A EGFR ERBB2 KRAS MMP9 PIK3CA
41
Show member pathways
12.74 AKT1 BAX CASP9 CDKN1A EGFR ERBB2
42
Show member pathways
12.72 AKT1 EGFR ERBB2 KRAS PIK3CA TP53
43
Show member pathways
12.72 AKT1 BAX ERBB2 ESR1 FOS KRAS
44
Show member pathways
12.71 AKT1 BAX CASP9 CDKN1A CYCS EGF
45
Show member pathways
12.67 AKT1 FOS KRAS PIK3CA
46
Show member pathways
12.65 AKT1 CASP9 EGF EGFR FOS KRAS
47
Show member pathways
12.63 AKT1 EGF EGFR FOS KRAS PIK3CA
48
Show member pathways
12.63 AKT1 BAX CASP9 CDKN1A FOS PIK3CA
49
Show member pathways
12.63 AKT1 BAX CASP8 CASP9 EGFR ERBB2
50
Show member pathways
12.62 AKT1 CDKN1A EGF EGFR KRAS PIK3CA

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
2 cytoplasm GO:0005737 9.86 AKT1 BAX CASP8 CASP9 CDKN1A CTSK
3 protein-containing complex GO:0032991 9.17 AKT1 CASP8 CASP9 CDKN1A EGFR ESR1

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.99 EGF EGFR ERBB2 KRAS
2 regulation of apoptotic process GO:0042981 9.99 AKT1 BAX CASP8 CASP9 ESR1 TP53
3 response to organic cyclic compound GO:0014070 9.92 CASP9 CDKN1A EGFR FOS
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 BAX CASP8 CASP9
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 AKT1 EGFR PIK3CA
6 positive regulation of cell growth GO:0030307 9.88 AKT1 EGFR ERBB2
7 response to estradiol GO:0032355 9.88 CASP8 CASP9 EGFR ESR1
8 cellular response to mechanical stimulus GO:0071260 9.87 AKT1 CASP8 EGFR
9 cellular response to organic cyclic compound GO:0071407 9.86 AKT1 CASP8 CASP9
10 liver development GO:0001889 9.86 EGFR KRAS PIK3CA RB1CC1
11 Ras protein signal transduction GO:0007265 9.85 CDKN1A KRAS TP53
12 cellular response to growth factor stimulus GO:0071363 9.85 AKT1 EGFR ERBB2
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.85 BAX CDKN1A TP53
14 positive regulation of fibroblast proliferation GO:0048146 9.84 CDKN1A EGFR ESR1
15 cellular response to UV GO:0034644 9.83 BAX CASP9 TP53
16 epidermal growth factor receptor signaling pathway GO:0007173 9.83 AKT1 EGF EGFR PIK3CA
17 cellular response to epidermal growth factor stimulus GO:0071364 9.82 AKT1 EGFR ERBB2
18 negative regulation of Notch signaling pathway GO:0045746 9.8 AKT1 EGF EGFR
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.79 AKT1 ERBB2 PIK3CA
20 response to antibiotic GO:0046677 9.78 CASP8 CASP9 TP53
21 regulation of cell motility GO:2000145 9.77 EGF EGFR ERBB2
22 positive regulation of phosphorylation GO:0042327 9.77 EGF EGFR TNFSF11
23 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.76 BAX MMP9 TP53
24 cellular response to cadmium ion GO:0071276 9.76 AKT1 EGFR FOS MMP9
25 cellular response to reactive oxygen species GO:0034614 9.73 AKT1 EGFR FOS MMP9
26 positive regulation of protein phosphorylation GO:0001934 9.73 AKT1 EGFR ERBB2 KRAS MMP9 RB1CC1
27 mammary gland alveolus development GO:0060749 9.72 EGF ESR1 TNFSF11
28 anoikis GO:0043276 9.7 AKT1 PIK3CA
29 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.7 ESR1 TP53
30 vagina development GO:0060068 9.69 BAX ESR1
31 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.68 EGFR TP53
32 response to cobalt ion GO:0032025 9.67 CASP8 CASP9
33 signal transduction by p53 class mediator GO:0072331 9.65 CDKN1A TP53
34 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.65 BAX CASP9 CYCS
35 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.63 BAX CASP8
36 positive regulation of protein kinase B signaling GO:0051897 9.63 EGF EGFR ERBB2 ESR1 PIK3CA TNFSF11
37 response to UV-A GO:0070141 9.62 AKT1 EGFR
38 ERBB2 signaling pathway GO:0038128 9.62 EGF EGFR ERBB2 PIK3CA
39 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGF EGFR ERBB2
40 intrinsic apoptotic signaling pathway GO:0097193 9.54 BAX CDKN1A TP53
41 positive regulation of MAP kinase activity GO:0043406 9.35 EGF EGFR ERBB2 KRAS TNFSF11
42 cytokine-mediated signaling pathway GO:0019221 9.23 AKT1 CDKN1A FOS KRAS MMP9 PIK3CA
43 phosphatidylinositol phosphorylation GO:0046854 9.19 PIK3CA
44 apoptotic process GO:0006915 10.15 AKT1 BAX CASP8 CASP9 CYCS TP53
45 positive regulation of transcription, DNA-templated GO:0045893 10.11 AKT1 EGF EGFR ESR1 FOS TP53
46 cellular response to DNA damage stimulus GO:0006974 10.09 AKT1 BAX CASP9 CDKN1A TP53
47 cell proliferation GO:0008283 10.06 AKT1 BAX EGFR ERBB2 TP53
48 positive regulation of apoptotic process GO:0043065 10.04 AKT1 BAX CASP9 MMP9 TP53
49 positive regulation of gene expression GO:0010628 10.04 AKT1 EGF ERBB2 KRAS TNFSF11 TP53
50 negative regulation of apoptotic process GO:0043066 10.01 AKT1 CDKN1A EGFR MMP9 RB1CC1 TP53

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 AKT1 BAX CASP8 EGFR ERBB2 ESR1
2 protein heterodimerization activity GO:0046982 9.85 BAX EGFR ERBB2 FOS TP53
3 ubiquitin protein ligase binding GO:0031625 9.77 CASP8 CDKN1A EGFR SLC22A18 TP53
4 protein phosphatase binding GO:0019903 9.61 EGFR ERBB2 TP53
5 protein kinase binding GO:0019901 9.5 AKT1 CASP9 CDKN1A EGFR ESR1 RB1CC1
6 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.4 CASP8 CASP9
7 nitric-oxide synthase regulator activity GO:0030235 9.33 AKT1 EGFR ESR1
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.32 PIK3CA
9 protein binding GO:0005515 10.28 AKT1 BAX CASP8 CASP9 CDKN1A CTSK

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....